Our Oncology Products

Welcome to the Pierre Fabre Oncology section

For more information and resources on our pharmaceutical products, including patient resources and medical education, please visit our website specific for Australian healthcare professionals via the link below.

This website contains information on products which is targeted to an Australian audience and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

BRAFTOVI
(encorafenib)

 

BRAFTOVI (encorafenib) is a BRAF inhibitor, indicated in Australia:

  • in combination with MEKTOVI (binimetinib) for the treatment of adult patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test
     
  • in combination with cetuximab for the treatment of adult patients who have metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, and who have received prior systemic therapy
     
  • in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation

See BRAFTOVI Product Information 

MEKTOVI
(binimetinib)

MEKTOVI (binimetinib) is a MEK inhibitor indicated in Australia:

  • in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test
     
  • in combination with BRAFTOVI (encorafenib) for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.

See MEKTOVI Product Information 

Website for Australian HCPs

For more information and resources on our pharmaceutical products, including patient resources and medical education, please visit our website.

Visit the Australian HCP Website